Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pacific Stem Cells markets umbilical cord- and placental‑derived stem cell products and related regenerative therapies directly to patients for multiple serious conditions without FDA‑approved biologics licenses or INDs; FDA issued an untitled letter in 2021 stating these are unapproved drugs/biologics and raising significant safety and regulatory concerns.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pacific Stem Cells.